ESC 365 - BA6b9, a novel sk4 K + channel blocker, attenuates atrial fibrillation substrate in rats with reduced ejection fraction

ESC Professional Premium Access

BA6b9, a novel sk4 K + channel blocker, attenuates atrial fibrillation substrate in rats with reduced ejection fraction

Session: Clinical and experimental arrhythmia treatments

Topic: Antiarrhythmic Drug Treatment

Speaker: Mr O. Levi (IL)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Mr Or Levi

(Israel)

0 follower

8 more presentations in this session

Efficacy and safety of ultrasound guided stellate ganglion block: developing new clinical indications beyond electrical storm

Speaker: Doctor A. Morena (Turin, IT)

Atrial and ventricular arrhythmias in young, lifelong and retired elite endurance athletes

Speaker: Doctor P. D'Ambrosio (Fitzroy, AU)

Analysis of safety and outcome of use of NOAC in intracardiac thrombi over warfarin

Speaker: Doctor O. Al-assaf (Dubai, AE)

Amiodarone-related thyroid dysfunction and associated outcomes in patients with heart failure - a matched case-control study

Speaker: Doctor S. Ali (Copenhagen, DK)

Association between preprocedural thromboembolic or bleeding events under oral anticoagulation therapy and mid-term outcomes after percutaneous left atrial appendage closure

Speaker: Doctor H. Sumiyoshi (Kurashiki, JP)

Access the full session

Clinical and experimental arrhythmia treatments

Speakers: Mr O. Levi, Doctor A. Morena, Doctor P. D'Ambrosio, Doctor O. Al-assaf, Doctor S. Ali...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources